Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

AGIO

AGIOS PHARMACEUTICALS, INC.

Pharmaceutical Preparations · SIC 2834CIK 1439222Held by 3 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$0.05B
Net Income FY2025
$(0.41B)
EPS (Basic, as reported)
$-7.12
Net Margin FY2025
-764.0%
ROE FY2025
-34.6%
Total Equity
$1.19B
Shares Out
60M
Business description

AGIOS PHARMACEUTICALS, INC. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2011–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 70 → 54 -2.8% CAGR
Revenue7043941180014273654
Cost of revenue00(1)(1)00(2)(3)(4)(6)
Research & development(220)(293)(341)(411)(367)(257)(280)(296)(301)(340)
Selling, general & administrative(51)(71)(114)(132)(149)(121)(122)(120)(157)(180)
General & administrative(51)(71)————————
Total operating expenses(271)(364)(457)(544)(519)(378)(403)(418)(462)(526)
Operating income(201)(321)(362)(426)(316)(378)(389)(391)(426)(472)
Interest & investment income3616157113———
Other income (expense), net———00147662
Pre-tax income(198)(315)(346)(301)(329)(357)(232)(352)718(414)
Income tax expense0000——00(44)(1)
Net income(198)(315)(346)(411)(327)1,605(232)(352)674(413)
EPS — basic———($6.86)($4.74)$26.55($4.23)($6.33)$11.86($7.12)
EPS — diluted———($6.86)($4.74)$26.55($4.23)($6.33)$11.64($7.12)
Shares outstanding — basic (M)———60696055565758
Shares outstanding — diluted (M)———60696055565858

Showing the latest 10 of 15 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.